Skip to main content

Table 1 Clinical characteristics of non-small cell lung cancer patients with different failure sites

From: Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study

Factor Total [cases (%)] CF [cases (%)] BF [cases (%)] OF [cases (%)] P
Total 307 192 32 83
Gender      0.010
 Male 135 (44.0) 90 (46.9) 19 (59.4) 26 (31.3)  
 Female 172 (56.0) 102 (53.1) 13 (40.6) 57 (68.7)  
Smoking history      0.242
 Never 229 (74.6) 145 (75.5) 20 (62.5) 64 (77.1)  
 Former/current 78 (25.4) 47 (24.5) 12 (37.5) 19 (22.9)  
Pathology      0.776
 Adenocarcinoma 298 (97.1) 186 (96.9) 31 (96.9) 81 (97.6)  
 Squamous 4 (1.3) 2 (1.0) 1 (3.1) 1 (1.2)  
 Adenosquamous 5 (1.6) 4 (2.1) 0 (0) 1 (1.2)  
Tumor stage      NA
 IIIA 52 (16.9) 51 (26.6) 0 (0) 0 (0)  
 IIIB 20 (6.5) 19 (9.9) 0 (0) 0 (0)  
 IV 235 (76.5) 122 (63.5) 32 (100) 83 (100)  
Initial EGFR mutation      0.656
 19del 163 (53.1) 106 (55.2) 18 (56.3) 39 (47.0)  
 L858R 121 (39.4) 74 (38.5) 11 (34.4) 36 (43.4)  
 Rare mutation 23 (7.5) 12 (6.3) 3 (9.4) 8 (9.6)  
Response      0.023
 SD 101 (32.9) 63 (32.8) 15 (46.9) 23 (27.7)  
 PR 180 (58.6) 116 (60.4) 17 (53.1) 47 (56.6)  
 CR 26 (8.5) 13 (6.8) 0 (0) 13 (15.7)  
  1. CF, progressive disease limited to the chest in lung/pleural tissues and lymph nodes, with no evidence of progression beyond the chest; BF, progressive disease in a previously existing site or a new site of metastatic disease in the brain, with no evidence of extracranial progression; OF, progressive disease in other distant sites or multiple sites including the chest and intracranial region
  2. EGFR epidermal growth factor receptor, CR complete response, PR partial response, SD stable disease